StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a research report sent to investors on Tuesday. The firm issued a hold rating on the stock.
Several other equities research analysts also recently commented on the stock. HC Wainwright reiterated a buy rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st. JMP Securities lifted their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a market outperform rating in a research note on Wednesday, July 31st.
Get Our Latest Report on DBV Technologies
DBV Technologies Trading Down 1.7 %
DBV Technologies (NASDAQ:DBVT – Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The firm had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. During the same period in the prior year, the firm posted ($0.26) earnings per share. As a group, sell-side analysts predict that DBV Technologies will post -1.43 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC acquired a new position in DBV Technologies S.A. (NASDAQ:DBVT – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Read More
- Five stocks we like better than DBV Technologies
- Stock Market Upgrades: What Are They?
- Emerging Markets: What They Are and Why They Matter
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Recession or Not, These 3 Stocks Are Winners
- How to Capture the Benefits of Dividend Increases
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.